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ABSTRACT 
Objective:  To see the effect of application of Vancomycin powder directly into the subgaleal space in reducing 
the postoperative surgical site infections. 
Materials and Methods:  All the patients who underwent consecutive elective craniotomies from April 2017 to 
May 2018 Department of Neurosurgery, Shaheed Zulfiqar Ali Bhutto Medical University, PIMS, Islamabad. The 
control group received the standard routine prophylaxis according to the hospital protocols, whereas the 
treatment group, in addition to the standard prophylaxis, received Vancomycin powder in the surgical wound in 
addition to the standard routine prophylaxis. Incidence of infection was the primary outcome evaluated. 
Results:  182 patients were enrolled in the study, 91 allocated to each the control and treatment group 
(Vancomycin). Six patients were lost to follow up.  There were 90 patients in the control group and 86 patients in 
the treatment (Vancomycin) group. Both the groups were almost statistically similar. In the control group, 
34.09% (n = 60) were male and 17.04% (n = 30) were female. In the treatment group, 29.54% (n = 52) were 
male and 19.31% (n = 34) were female. The overall rate of surgical site infection (SSI) was 3.97% (7 out of 176 
cases). A statistically significant difference found in infection rate between the treatment group, 0% (0 out of 86 
cases) and the control group, 7.77% (7 out of 90 cases) with the p value of 0.002. We did not observed any 
adverse effects from the use of the Vancomycin powder. 
Conclusions:  The use of topical Vancomycin powder in surgical wounds may significantly reduce the incidence 
of infection in patients undergoing elective craniotomies. It is a promising means of preventing devastating and 
harmful postoperative wound infections. 
Key Words:  Vancomycin; cranial surgery; surgical site infection. 
Abbreviations:  SSI: Surgical Site Infection. 
 
INTRODUCTION 
Neurosurgery or neurological surgery is the 
subspecialty in surgery, which deals with the 
prevention, diagnosis, surgical treatment and 
rehabilitation of the diseases of the nervous system. 
The organs involved are the brain, spinal cord, 
peripheral nerves, and extra-cranial cerebrovascular 
system. Some of the common surgical procedures 
performed in neurosurgery include management of 
congenital malformations, epilepsy surgery, functional 
neurosurgery, surgical management of vascular 
conditions of the brain and spinal cord and surgery of 
the peripheral nervous system. 
 A craniotomy is an incision through the skull done 
to excise, repair, or explore the brain, and a 
craniectomy is a procedure in which a portion of the 
skull is excised (i.e., removed) surgically to access the 
brain.
1
 Both craniotomy and craniectomy (CRANI) 
procedures are used worldwide by the neurosurgeons 
to treat different disorders of the brain including: brain 
tumors, traumatic and spontaneous blood clots, 
bleeding into the brain parenchyma (hemorrhage), 
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vascular pathologies such as  defects in blood vessels 
(cerebral aneurysms, or atherosclerosis), abnormal 
blood vessels (arteriovenous malformations), damage 
to tissues covering thebrain (dura), localized infections 
(brain abscesses), diffuse infections (epidural 
abscesses, subdural empyema) severe nerve or facial 
pain (trigeminal neuralgia or tic douloureux), trauma 
to the skull (skull fractures) and some seizure 
disorders (epilepsy).
2
 
 The number of CRANI done per year is gradually 
increasing all over the world. Alone in US more than 
100,000 procedures are performed each year.
3
 Surgical 
Site Infection (SSI) is major problem for all of the 
surgeons around the world and has catastrophic 
consequences resulting in increased morbidity, 
prolonged in hospital stay, reduced life quality, 
increased costs, unplanned readmissions and 
mortality.
4
 A recent prevalence study states that SSI 
accounts for 31% of all healthcare associated 
infections.
5
 The rate of developing SSI after a 
neurosurgical procedure should ideally be low because 
in proximity to them there are no potentially 
contaminated fields like gastrointestinal or urogenital 
tract. But, they are in close proximity with the 
cerebrospinal fluid (CSF) and central nervous system, 
both of which are sterile.
6
 The rate of  postoperative 
complicated CRANI cases with SSI is 2.2 – 4.7%.7 
However, in low and middle-income setups slightly 
higher rates are reported. In Malaysia, a study reported 
the SSI rate after CRANI procedures to be 7.7%.
8
The 
economic magnitude of burden is reported as much as 
£9283 for each SSI after CRANI.
9
 The main objective 
of our study was to assess the overall rate of SSI after 
CRANI at Department of Neurosurgery, Shaheed 
Zulfiqar Ali Bhutto Medical University and to evaluate 
the role of local Vancomycin powder application into 
the CRANI wound in effective prophylaxis of SSI 
after CRANI. 
 
PATIENTS AND METHODS 
Study Design and Sampling 
This Randomized controlled trial (RCT) was carried 
out from April 2017 to May 2018 at the department of 
Neurosurgery, Shaheed Zulfiqar Ali Bhutto Medical 
University, PIMS, Islamabad. The sample was 
gathered by using non-probability consecutive 
sampling method with 91 patients in each group. The 
sample size was calculated by keeping Level of 
significance = 5%, Power of test = 95%, Surgery with 
Vancomycin powder = (P1) 0%,
6
 Surgery without 
Vancomycin powder = (P2) 13%.
6
 
 
Inclusion Criteria 
Patients of both genders undergoing craniotomy/ 
craniectomy were included in our study. 
 
Exclusion Criteria 
Children under age of 3 years, Patients with prior 
history of infection at the surgical site, patients 
undergoing biopsy or patients with burr hole 
placement only, allergic to Vancomycin. Patients who 
develop a CSF leak and those with serious medical 
illnesses were excluded from the study. 
 
Data Collection 
The study started after taking approval from the 
hospital ethics committee. All patients who were 
admitted to Neurosurgery ward and underwent 
CRANIL procedures were enrolled in the study. 
Informed written consent was taken from each patient. 
Initial data about age, contact number and date of 
admission was recorded on predesigned Proforma. All 
patients received an intravenous dose of 1g of 
Ceftriaxone 30 minutes before incision. All the 
patients were scrubbed with pyodine scrub and spirit. 
In one group of patient’s Vancomycin powder was 
applied to the bone flap, and subgaleal space before 
closing the wound. In the control group no 
Vancomycin powder was applied. The patients were 
randomized to group A (with intrawound Vancomycin 
application) and group B (without Vancomycin 
application) by lottery method. The procedure was 
performed under general anesthesia in all patients by 
consultant Neurosurgeon. Post operatively patients 
were kept in Head Injury Unit or Surgical Ward 3 
accordingly. The wound was examined on 3
rd
, 5
th
 and 
7
th
 postoperative days for any signs of SSI. On full 
recovery patients were discharged from hospital. The 
patients were followed after 30 days and wound was 
thoroughly examined again for any signs of SSI. 
 
Data Analysis 
The data was entered in SPSS version 20. Descriptive 
statistics were used to calculate means ± standard 
deviation for quantitative variables i.e. age. 
Frequencies with percentage were calculated for 
qualitative variables, i.e. gender, occurrence of CSF 
leak and treatment efficacy. The Chi-square test was 
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used to compare surgical site 
infection at post-operative days 3, 5, 
7, at the time of discharge and at 
30
th
 day. The efficacy was compared 
by applying chi-square test between 
both groups. Effect modifiers like 
age and gender were controlled by 
stratification. Post stratification chi-
square test was applied. 
 
RESULTS 
We enrolled 182 patients in our 
study who underwent consecutive 
elective craniotomy procedures 
from April 2017 to May 2018 at the 
department of Neurosurgery, 
Shaheed Zulfiqar Ali Bhutto 
Medical University, Pakistan 
Institute of Medical Sciences 
(PIMS) Islamabad. In all, six 
patients, who lost to follow-up. 
 
Gender Distribution 
Males were predominant. 63.63% 
(n = 112) were male and 36.36% 
(n = 64) were female. In the control 
group, 34.09% (n = 60) were male 
and 17.04% (n = 30) were female. 
In the treatment group, 29.54% (n = 
52) were male and 19.31% (n = 34) 
were female. 
 
Age Incidence 
Among the 176 patients, the 
youngest was 15 years old and the 
oldest patient was 75 years old with 
a mean age of 47.95 years and a 
standard deviation of 12.03. The 
highest number of patients was 
between ages 50 and 60 i.e., 63 with 
the lowest number of patients above 
age 70. 
 
Infection 
Out of the 176 patients included in 
our study, seven (3.97%) surgical 
site infections were encountered. In 
the 86 patients included in the 
Table 1:  SSI in both the groups (Application of chi-square). 
 
SSI Status 
Study Group 
Total 
P value 
Chi-square 
Control Vancomycin 
0.002 
Present 7 (3.97%) 0 (0%) 7 (3.97%) 
Absent 83 (47.15%) 86 (48.86%) 169 (96.02%) 
Total 90 (51.14%) 86 (48.86%) 176 (100%) 
 
Table 2:  Surgical site infection distribution by gender. 
 
 
SSI Status 
Total 
P value 
Chi-
square Present Absent 
Gender 
Male  5 (4.46%) 107 (95.53%) 112 (100%) 
0.656 Female  2 (3.12%)   62 (96.87%)   64 (100%) 
Total  7 (3.97%) 169 (96.02%) 176 (100%) 
 
Table 3:  Surgical Site Infection at day 3. 
 
SSI 
Status 
Study Group 
Total 
P value 
Chi-square 
Control Vancomycin 
0.016 
Present 2 (1.13%) 0 (0%) 2 (1.13%) 
Absent 88 (50%) 86 (48.86%) 174 (98.86%) 
Total 90 (51.13%) 86 (48.86%) 176 (100%) 
 
Table 4:  Surgical Site Infection at day 5. 
 
SSI 
Status 
Study Group 
Total 
P value 
Chi-square 
Control Vancomycin 
0.038 
Present 4 (2.27%) 0 (0%) 4 (2.27%) 
Absent 86 (48.86%) 86 (48.86%) 172 (97.72%) 
Total 90 (51.13%) 86 (48.86%) 176 (100%) 
 
Table 5:  Surgical Site Infection at day 7. 
 
SSI 
Status 
Study Group 
Total 
P value 
Chi-square 
Control Vancomycin 
0.234 
Present 1 (0.56%) 0 (0%) 1 (0.56%) 
Absent 89 (50.56%) 86 (48.86%) 175 (99.06%) 
Total 90 (51.13%) 86 (48.86%) 176 (100%) 
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treatment group there was no SSI 
identified. Ninety patients were 
allotted to the control group and 
seven (7.77%) SSIs were identified. 
Out of the 112 males included in 
this study, 4.46% (n = 5) developed 
SSI. On the other hand, in the 64 
females only 3.12% (n = 2) SSIs 
were identified. The patients in the 
7
th
 decade of their life suffered from 
SSIs more as compared to the other 
age groups. In this age group, the
Table 6:  Surgical Site Infection at day 30. 
 
SSI Status 
Study Group 
Total 
P value 
Chi-square 
Control Vancomycin 
0.234 
Present 0 (0%) 0 (0%) 0 (0%) 
Absent 90 (51.13%) 86 (48.86%) 176 (100%) 
Total 90 (51.13%) 86 (48.86%) 176 (100%) 
 
SSI rate was 16% (4 out of 25) followed by 3.17% (2 
out of 61) infected cases in the age group of 6
th
 decade 
of life. Our results showed  that overall 7.77% (7 out 
of 90 patients) in the control group suffered from SSIs 
as compared to the treatment group with no SSIs in 86 
patients. This is statistically significant as the p value 
turned out to be 0.002. On day 3 two SSIs were 
diagnosed in two patients (one a 58 year old male and 
other a 60 year old female). On day five, we diagnosed 
four patients with SSI and one SSI was diagnosed on 
day 7. In the treatment group, no patients 
demonstrated post-operative SSI (p > 0.05). In those 
patients diagnosed with SSIs, swabs from wounds 
were sent for culture and sensitivity and were started 
empiric antimicrobial therapy with Vancomycin/ 
Amikacin combination soon after. The causative 
pathogens were Staphylococcus aureus in four patients 
and Staphylococcus Epidermidis in three. 
 
DISCUSSION 
SSI after neurosurgical procedures is a huge problem 
for neurosurgeons as they are a major source of 
morbidity and mortality. In general, neurosurgeons 
have reported postoperative SSI rates to be lower than 
those reported by other surgical specialists have. 
However, with the advancement in the technology, 
surgical microscopes and endoscopes have been 
introduced which has led to a prolonged neurosurgical 
procedure. Along with that increasing use of implants 
and other foreign material such as shunts, spinal 
implants, cranioplasty plates/mesh, and artificial dural 
substitutes have increased the risk of postoperative 
SSIs. Overall rate of SSIs in neurosurgical 
departments has been reported to be from 0% to 15%. 
SSI rate after CRANI procedures is about 6%.
8
 
Throughout the years, many measures have been 
developed and implemented to decrease the SSIs; they 
include preoperative preparation of the patient, 
clipping the hair, proper surgeon’s preparation, 
prophylactic antibiotics and the latest option added to 
it is sprinkling Vancomycin powder into the surgical 
wound. Although it has been studied extensively in 
spine surgeries and have, shown benefit as reported by 
some authors to decrease the SSIs from 15% to 0%
9
 
still in cranial surgery it is being evaluated and there is 
less literature published. 
 Our study, which was a randomized control trial 
and enrolled 182 consecutive patients undergoing 
elective clean cranial neurosurgery conducted at 
Department of Neurosurgery, Shaheed Zulfiqar Ali 
Bhutto Medical University from April 2017 until May 
2018. The study was conducted with a view to 
establish the efficacy of topical Vancomycin powder 
into the surgical wound in decreasing the SSIs, 
following non-traumatic, clean neurosurgical 
procedures. It will be helpful in reducing the rate of 
SSIs in our setups and other developing countries. 
 Our study included 182 patients, 91 in each group, 
but six patients were lost to follow up. Ages of 176 
patients ranged from 15 – 75 years. Most of the 
patients (156, 88.63%) were in between 30-69 years 
with mean age of 47.95 years. The mean age of the 90 
patients enrolled in the control group was 49.47 years 
with standard deviation of 11.89. The mean age of the 
86 patients in the treatment group was 46.36 years 
with standard deviation of 12.03. In a similar study 
performed at the Department of Neurosurgery, 
Hospital of the University of Pennsylvania and 
published in The Journal of Neurosurgery, the number 
of patients was 150 with a mean age of 52.1 ± 16.6 
years in the control group and 49.4 ± 15.6 in the 
treatment group.
10
 
 Another large prospective cohort study included 
three hundred and fifty five patients. Two hundred and 
five patients received Vancomycin in the subgaleal 
space after CRANI procedures. The mean ages of the 
patients in both the groups were reported to be higher 
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with 54.5 ± 2.5 years in the control group and 52.4 ± 
2.2 in the treatment group.
11
 
 In this study, we observed that of the 176 patients, 
seven developed surgical site infections, thus the 
overall rate of SSI in our study turned out to be 3.97%. 
All of the SSIs were deep incisional infections that 
required surgical intervention. Our findings are 
consistent with the SSI rate reported by Abdullah et al. 
They had six infected cases out of 150 patients and the 
overall SSI incidence was 4%.
12
 Similarly, another 
large study including 2865 patients undergoing 
craniotomy procedures reported overall SSI rate of 
3.6% (104 out of 2865).
3
 Our findings are almost 
consistent with both these studies. However, our SSI 
rate is higher than the 2.2% that was reported by 
Ravikumar et al in a similar study.
13
 It is also higher 
than the SSI rate of 2.2% reported by multiple 
hospitals to the National Healthcare Safety Network.
11
 
 Of the 75 patients in the control group, Abdullah 
et al reported five SSIs and in the treatment group, 
they had only one infected case out of 75 patients.
14
 
Our findings are consistent with their findings as we 
had seven SSIs out of the 90 patients in the control 
group and no SSI in the 86 patients in the treatment 
group. 
 Mallela et al. in their study included 150 patients 
in the control group and 205 patients in the treatment 
group. They had 9 (6%) in the control group and only 
1 (0.49%) in the treatment group.
16
 Our findings are 
consistent with the findings of this study. In our study, 
we had seven (7.77%) SSIs out of 90 patients in the 
control group; however, we had no infected case in in 
the treatment group. 
 Regarding the sex distribution in our study, out of 
the 176 patients 112 (63.6%) were male and 64 
(36.4%) were female. Male to female ratio was 1.75:1. 
The rate of SSIs among males was 4.46% (5 out of 
112) and in females was 3.12% (2 among 64). The rate 
of SSIs was slightly higher in males, but statistically 
not significant (p value 0.65). These findings are 
consistent with the findings of Abdullah et al, Mallela 
et al. and Ravikumar et al., where they could not find 
any statistically significant association between gender 
and SSIs.
11,12,14
 
 The rate of surgical site infections (SSIs) in 
different age groups was 3.17% (2 out of 63) in the 
age group 50-59 years, 16% (4 out of 25) in 60 – 69 
years and 100% (1 out of 1) in the 70 – 79 years. It 
was highest 16% in the age groups 60 – 6 % (4 out of 
25 patients).Out of the seven infected cases 2 (1.13%) 
were identified on 3
rd
 post-operative day, 4 cases on 
the 5
th
 post-operative day and 1 on the 7
th
 post-
operative day (p > 0.05). Similar results have been 
reported in other studies as well.
15-20
 
 
CONCLUSION 
Our study demonstrates that the use of topical 
Vancomycin powder into the craniotomy wound is 
associated with decreased rate of surgical site infection 
(SSIs). The findings suggest that the topical 
Vancomycin powder is effective, safe and leads to 
decrease costs. These results are comparable to 
international studies quoted earlier and have been 
practiced by various other specialties as well. 
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